Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally
JV will have global marketing rights to oral drug delivery technology HTIT to invest $60 million , Oramed to invest $10 million into JV HTIT to provide a supply agreement for oral insulin capsule JV to advance registration of oral insulin in the United States and other countries NEW YORK , Aug.
